Bromocriptine (Parlodel): Uses, Dosage, and Side Effects
Complete guide to bromocriptine: Understanding dosage, uses, and side effects.
What is Bromocriptine (Parlodel)?
Bromocriptine is a synthetic oral medication classified as a dopamine D2 receptor agonist. It belongs to a group of drugs related to ergot alkaloids and works by stimulating dopamine receptors in the brain and hypothalamus. The medication is available under multiple brand names, including Parlodel and Cycloset, and has been used clinically for several decades to treat various hormonal and neurological conditions.
How Does Bromocriptine Work?
Bromocriptine functions as a dopamine receptor agonist, which means it activates dopamine type-2 receptors while antagonizing dopamine type-1 receptors in the hypothalamus and neostriatum of the central nervous system. This dual mechanism of action enables the medication to address multiple physiological pathways.
In the tuberoinfundibular pathway, dopamine acts as a prolactin-inhibitory factor. By stimulating dopamine receptors in this region, bromocriptine effectively reduces prolactin secretion from the anterior pituitary gland. In the corpus striatum, dopaminergic neurons regulate motor function; by directly stimulating dopamine receptors here, bromocriptine helps restore motor control in Parkinson’s disease patients.
Additionally, bromocriptine demonstrates effectiveness in treating acromegaly by lowering elevated blood levels of growth hormone in the majority of patients.
Approved Uses and Indications
Parkinson’s Disease
Bromocriptine is indicated for treating idiopathic or postencephalitic Parkinson’s disease. The medication is used as adjunctive therapy alongside levodopa in patients who are already receiving optimal dosages of levodopa or who are beginning to show tolerance to levodopa therapy. However, it is important to note that use for newly diagnosed Parkinson’s disease is limited, as significantly more adverse reactions occur in bromocriptine-treated patients compared to those receiving levodopa/carbidopa combinations.
Hyperprolactinemia and Related Conditions
Bromocriptine is a primary treatment for hyperprolactinemia-associated dysfunctions, which include:
- Amenorrhea (absence of menstruation) with or without galactorrhea (abnormal milk production)
- Hypogonadism (abnormally low levels of sex hormones)
- Infertility related to high prolactin levels
- Galactorrhea and nipple discharge from abnormal milk production
- Prolactin-secreting pituitary adenomas (benign tumors)
Clinical data shows that bromocriptine significantly reduces plasma prolactin levels in patients with both physiologically elevated and pathologically elevated prolactin.
Acromegaly
Bromocriptine is used as monotherapy or adjunctive therapy alongside pituitary irradiation or surgery in acromegaly patients. In many acromegalic patients, the medication produces a prompt and sustained reduction in circulating growth hormone levels, with bromocriptine reducing serum growth hormone by 50% or more in approximately half of treated patients.
Type 2 Diabetes Mellitus
The micronized formulation of bromocriptine (marketed as Cycloset) is used in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. This newer indication represents an expansion of the medication’s therapeutic applications beyond its traditional uses.
Off-Label Uses
Bromocriptine has been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome (NMS). For mastalgia associated with premenstrual syndrome, doses of 2.5 mg twice daily given cyclically have been studied, though the frequency and severity of adverse effects often limit its use for this indication.
Dosage Information
Parkinson’s Disease
For Parkinson’s disease treatment, the initial dose typically ranges from 1.25 mg to 2.5 mg daily, taken at bedtime with food. The dose is then gradually increased by 1.25 to 2.5 mg daily at intervals of 3 to 7 days until the optimal therapeutic effect is achieved. The typical maintenance dosage is 20 mg to 30 mg daily, with a maximum of 30 mg per day in clinical practice.
Acromegaly
Treatment of acromegaly begins with an initial dose of 1.25 mg to 2.5 mg once daily at bedtime (taken with food) for 3 days. The dose may be increased by 1.25 to 2.5 mg daily at 3 to 7 day intervals until optimal therapeutic effect occurs. Typical maintenance dosage is 20 mg to 30 mg daily in divided doses, commonly divided every 6 hours with food. The maximum dosage is generally 100 mg daily in divided doses, although literature indicates doses rarely exceed 60 mg daily.
Hyperprolactinemia-Associated Dysfunctions
Initial dosing for hyperprolactinemia conditions is 1.25 to 2.5 mg once daily. The dose may be increased by 2.5 mg daily every 2 to 7 days until optimal therapeutic response is achieved. The typical dose range is 2.5 to 15 mg daily.
Prolactin-Secreting Pituitary Adenoma
Initial dose is 1.25 to 2.5 mg once daily, with dose increases of up to 2.5 mg daily every 2 to 7 days. The typical dose range is 2.5 to 10 mg daily. Research indicates that of studied patients (n=14), 9 had successful outcomes, 3 had partial responses, and 2 patients did not respond.
Type 2 Diabetes (Cycloset)
When used for type 2 diabetes as Cycloset, the dosing schedule differs and should be determined by a healthcare provider as an adjunct to diet and exercise.
Common Side Effects
Bromocriptine can cause various side effects, with some occurring early in treatment and others developing later. The most commonly reported adverse effects include:
- Constipation (delayed onset, 5.8-14.0% incidence)
- Hypoglycemia (early onset, 3.7-8.6% incidence)
- Amblyopia (vision problems, delayed onset, 5.3-7.5% incidence)
- Orthostatic hypotension (low blood pressure upon standing, 0.3-6.0% incidence)
- Nausea and dizziness
- Headaches and fatigue
- Sleep disturbances and insomnia
Serious Side Effects and Precautions
While many side effects are mild, bromocriptine can cause serious adverse effects that require medical attention:
- Retroperitoneal fibrosis: Fibrotic changes in tissues surrounding the kidneys and abdomen; bromocriptine should be withdrawn if these changes are diagnosed or suspected
- Visual field changes: Secondary deterioration of visual fields may develop despite normalized prolactin levels, potentially resulting from traction on the optic chiasm
- Cardiovascular effects: Bradycardia (slow heart rate) and vasovagal attacks have been reported
- Neuropsychiatric effects: Delusions, paranoia, and psychosis have occurred
- Other serious effects: Vertigo, paresthesia (abnormal sensations), reduced cold tolerance, and muscle cramps
Patients should be monitored for these manifestations, particularly in early treatment stages. Visual hallucinations, lassitude (lack of energy), shortness of breath, and heavy-headedness have also been documented.
Drug Interactions and Contraindications
Bromocriptine should not be used during breastfeeding or during the postpartum period. Healthcare providers must review all current medications with patients, as dopamine agonists can interact with other drugs affecting the dopaminergic system.
Special Considerations for Specific Conditions
Pituitary Adenomas and Visual Changes
In patients with prolactin-secreting adenomas, bromocriptine treatment typically leads to reduction in hyperprolactinemia and often results in visual field improvement by reducing tumor size. However, some patients may experience secondary deterioration of visual fields despite normalized prolactin levels, which may result from traction on the optic chiasm pulled down into the now partially empty sella turcica.
Advanced Parkinson’s Disease
In patients with advanced Parkinson’s disease who are already receiving optimal levodopa dosages, bromocriptine may provide additional therapeutic benefits. Healthcare providers may gradually decrease levodopa dosage while titrating bromocriptine until the optimum balance is determined.
Levodopa Tolerance
Patients beginning to deteriorate or develop tolerance to levodopa therapy may benefit from bromocriptine as adjunctive therapy.
Treatment Response Timeline
The timeline for therapeutic response varies by condition and individual patient factors. Some patients may experience response within weeks of initiating therapy, while others may require months of treatment. In Parkinson’s disease particularly, some patients may fail to respond even after 12 months of therapy.
Frequently Asked Questions
Q: What is the difference between Parlodel and Cycloset?
A: Parlodel is the original bromocriptine formulation used for Parkinson’s disease, hyperprolactinemia, and acromegaly. Cycloset is a micronized formulation specifically approved for type 2 diabetes as an adjunct to diet and exercise.
Q: Can bromocriptine be used for newly diagnosed Parkinson’s disease?
A: Data are insufficient to evaluate the potential benefit of bromocriptine for newly diagnosed Parkinson’s disease, and it causes significantly more adverse reactions compared to levodopa/carbidopa combinations. It is primarily used as adjunctive therapy in patients already receiving levodopa.
Q: How long does it take for bromocriptine to work for hyperprolactinemia?
A: Bromocriptine significantly reduces plasma prolactin levels and can produce prompt clinical effects in some patients. However, individual response timelines vary, and optimal therapeutic response may take several weeks to months.
Q: What should I do if I experience vision problems while taking bromocriptine?
A: Vision changes, including amblyopia and visual field changes, are potential side effects of bromocriptine. Report any visual symptoms to your healthcare provider immediately, as they may require dosage adjustment or discontinuation of the medication.
Q: Is bromocriptine safe during pregnancy?
A: Bromocriptine is contraindicated during breastfeeding and the postpartum period. Consult with your healthcare provider about safety during pregnancy, as individual assessment is required.
Q: Can bromocriptine cause blood sugar changes?
A: Yes, hypoglycemia (low blood sugar) is a documented side effect occurring early in treatment with an incidence of 3.7-8.6%. Patients, particularly those with diabetes, should monitor blood sugar levels and report significant changes to their healthcare provider.
Q: What should I avoid while taking bromocriptine?
A: Avoid abrupt discontinuation without consulting your healthcare provider. Be cautious with activities requiring alertness if experiencing dizziness or visual disturbances. Do not take bromocriptine during breastfeeding.
References
- Parlodel (bromocriptine mesylate) tablets, USP – Label — U.S. Food and Drug Administration. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/017962s083lbl.pdf
- Parlodel (bromocriptine mesylate) – Drug Summary — Physicians’ Desk Reference (PDR). https://www.pdr.net/drug-summary/Parlodel-bromocriptine-mesylate-1808
- PARLODEL CAPSULES Prescription & Dosage Information — Medical Professionals Reference (MPR). https://www.empr.com/drug/parlodel-capsules/
- Bromocriptine: Uses, Interactions, Mechanism of Action — DrugBank. https://go.drugbank.com/drugs/DB01200
- Bromocriptine (oral route) – Side effects & dosage — Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/bromocriptine-oral-route/description/drg-20062385
- Bromocriptine – StatPearls — National Center for Biotechnology Information (NCBI) Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK555948/
- Bromocriptine (Cycloset): Uses & Side Effects — Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/20842-bromocriptine-capsules-or-tablets
Similar Articles
Read full bio of Sneha Tete
